Affymetrix and Leica Biosystems Announce the Launch of Fully Automated RNA in situ Hybridization Assays
May 08 2014 - 4:30AM
Business Wire
ViewRNATM eZ Assays, fully automated on the Leica BOND RX, offer
remarkable sensitivity and specificity of staining for coding and
non-coding markers in an easy-to-use, fully automated format.
Affymetrix, Inc. (NASDAQ:AFFX) and Leica Biosystems announce the
launch of Affymetrix’ fully automated RNA in situ hybridization
assays ViewRNATM eZ Assays on the Leica BOND RX staining
platform. These assays detect coding RNA as well as novel
non-coding markers in formalin-fixed paraffin-embedded (FFPE)
tissues. Dedicated for research use only*, the assays provide
researchers with a powerful automated solution for drug discovery,
translational research, and the development of new diagnostic tests
for personalized medicine. The automation significantly reduces
hands-on time and assay run time for profiling single-cell gene
expression.
The Leica BOND RX system automates the staining process,
bringing all the benefits of consistency, reduced labor, and speed.
This fully automated assay is hands-free from tissue de-waxing to
counter staining, and offers high sensitivity, specificity, and
reproducibility with easy standardization across laboratories.
ViewRNA eZ Assays represent a major technological advancement
offering a robust and reliable platform to easily interrogate the
function and disease relevance of any expressed genes.
“In particular, the ability to target non-coding as well as
coding transcripts opens up a significant new capability to
discover powerful new biomarkers for molecular test development, as
the importance of the non-coding regions of the transcriptome are
becoming more and more evident,” said Andrew Last, PhD, Chief
Operating Officer at Affymetrix. “In addition, researchers can now
design probes to visualize RNA transcripts coding for secreted
proteins, which are important targets that traditional
immunohistochemistry assays have challenge detecting.”
Micah Litow, Director, Research & Innovation, Advanced
Staining Instruments at Leica Biosystems added: “Leica is very
excited that the BOND RX is fully automating the Affymetrix ViewRNA
eZ Assays. We are proud to have put such a powerful tool into the
hands of the dedicated researchers who are making important
discoveries, increasing our knowledge and improving cancer
diagnostics.”
Affymetrix’ ViewRNA eZ Assays on the Leica BOND RX platform are
now available for research applications. The ViewRNA eZ staining
protocol is pre-loaded onto the Leica BOND RX, and the staining kit
optimized for FFPE samples and probes of choice are available from
Affymetrix.
*For Research Use Only. Not for use in diagnostic
procedures.
PLEASE NOTE: Affymetrix, the Affymetrix logo, and ViewRNA
are trademarks of Affymetrix, Inc. All other trademarks and product
names are the property of their respective owners.
About Leica Biosystems
Leica Biosystems is a global leader in workflow solutions and
automation, striving to advance cancer diagnostics to improve
patients’ lives. Leica Biosystems provides anatomical pathology
laboratories and researchers a comprehensive product range for each
step in the pathology process, from sample preparation and staining
to imaging and reporting. Leica’s easy-to-use and consistently
reliable offerings help improve workflow efficiency and diagnostic
confidence. The company is represented in over 100 countries and is
headquartered in Nussloch, Germany.
About Affymetrix
Affymetrix technologies enable multiplex and simultaneous
analysis of biological systems at the cell, protein, and gene
level, facilitating the rapid translation of bench-top research
into clinical and routine use for human health and wellness.
The Company provides leadership and support, partnering with
customers in pharmaceutical, diagnostic, and biotechnology
companies, as well as leading academic, government, and non-profit
research institutes in their quest to use biology for a better
world.
More than 2,300 microarray systems have been shipped around the
world and more than 65,000 peer-reviewed papers have been published
citing Affymetrix technologies. Affymetrix is headquartered in
Santa Clara, California, and has manufacturing facilities in
Cleveland, Ohio, San Diego, Vienna, and Singapore. The Company has
about 1,100 employees worldwide and maintains sales and
distribution operations across Europe, Asia, and Latin America. For
more information about Affymetrix, please visit
www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2013, and other SEC reports for subsequent
quarterly periods.
Affymetrix, Inc.Media:Mindy Lee-Olsen,
408-731-5523Vice President, Marketing
Servicesmindy_lee-olsen@affymetrix.comorInvestors:Doug
Farrell, 408-731-5285Vice President, Investor
Relationsdoug_farrell@affymetrix.comorLeica
BiosystemsMedia:Tim Lyons, +61 (0) 400 990 975Global
Marketing Communications
Directortim.lyons@LeicaBiosystems.comwww.LeicaBiosystems.com
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2023 to Aug 2024